Core Viewpoint - The article emphasizes the collaboration between doctors, CEOs, engineers, and investors to address challenges in medical device innovation through a workshop organized by Shanghai Jiao Tong University School of Medicine and its affiliated institutions [1][4]. Training Highlights - The workshop aims to merge medical pain points with engineering technology to create innovative medical products and facilitate results transformation [4]. - Participants will learn the Biodesign innovation methodology, which is a global leading model for medical engineering innovation, focusing on efficient transformation [5]. - The program includes insights into the medical device industry trends, practical empowerment through design thinking and interdisciplinary collaboration, and opportunities for project exposure to potential investors [5]. Target Audience - The workshop is suitable for various professionals, including doctors from different departments, engineering personnel from research institutions, industry and investment practitioners, and entrepreneurs interested in medical device innovation [5]. Course Structure - The two-day intensive training covers medical innovation and technology layout, innovation practice, team exercises, and discussions on the key paths from concept to market [6][10]. - The first day includes sessions on medical innovation, technology layout, and practical exercises to foster collaboration among participants [6][8]. - The second day focuses on innovation industrialization and funding pathways, including discussions on financing, government support policies, and investment opportunities [12][15]. Expert Faculty - The workshop features a team of distinguished experts from Shanghai Jiao Tong University, including leaders in biomedical engineering and medical technology innovation, who will share their insights and experiences [13][16]. Registration Information - The workshop is scheduled for June 21-22, 2025, at Shanghai Jiao Tong University School of Medicine, with a fee of 8999 yuan per person, covering course materials and refreshments [9][18].

Core Viewpoint - The announcement highlights that the company's wholly-owned subsidiary, Gaoshi Tailiang Medical Technology Co., Ltd., has received medical device registration approval from the Guangdong Provincial Drug Administration for its "artificial lens implantation system" [1] Group 1: Product Details - The artificial lens implantation system is designed for use in micro-incision cataract surgery, optimizing the surgical incision to less than 1.8mm, which minimizes corneal trauma and accelerates postoperative recovery [1] - The product is an original design by Gaoshi Tailiang and has been granted an invention patent [1] Group 2: Regulatory Approval - The approval from the Guangdong Provincial Drug Administration marks a significant milestone for the company, as it allows the commercialization of the new artificial lens implantation system [1] - This system is compared to the one approved in 2024, indicating advancements in surgical techniques and technology [1]

Core Insights - The National Medical Products Administration has included Suzhou Yunhejing New Material Technology Co., Ltd.'s "Surface Porous Polyether Ether Ketone Interbody Fusion Device" in the special review list for innovative medical devices, marking a significant achievement for the company and the Taicang region [1] - Taicang's medical device industry has shown rapid growth, with nearly 100 production enterprises and a total of around 300 Class II and III medical device registration certificates obtained, along with over 500 Class I medical device filings [2] - The establishment of a global procurement and supply chain center by PerkinElmer in Taicang is expected to inject new momentum into the high-quality development of the local medical device industry [2] Company Developments - Suzhou Yunhejing's interbody fusion device utilizes patented technology to create a PEEK device with a connected porous structure, addressing clinical challenges related to traditional PEEK devices [1] - Zhuoran Medical Technology's biological hernia repair patch has achieved breakthroughs in key technologies, filling several domestic and international technical gaps [1] Industry Support Mechanisms - The introduction of a "special class docking + customized service" mechanism aims to provide tailored support for enterprises, with over 70 services conducted in the biopharmaceutical industry this year [4] - Active collaboration with provincial review and inspection experts has facilitated targeted guidance for enterprises, addressing critical technical issues in the registration process [6] - The Taicang Market Supervision Bureau is committed to enhancing the efficiency of the Jiangsu Provincial Drug Administration's review and inspection work station, promoting the rapid transformation and application of innovative biopharmaceutical achievements [8]

Financial Data and Key Metrics Changes - Worldwide revenue for Q1 2025 reached $47.3 million, representing approximately 25% growth compared to the prior year [6][26] - U.S. revenue was $44.8 million, reflecting approximately 27% growth, driven by a 27.3% increase in procedure volume [7][26] - Gross profit was $37.7 million, an increase of $7.8 million or 26.2%, with a gross margin rate of 79.7% [27] - Net loss narrowed to $6.5 million or $0.15 per diluted share, compared to a net loss of $10.9 million or $0.27 per diluted share in the prior year [28] - Positive adjusted EBITDA of approximately $5 million compared to an adjusted EBITDA loss of $4 million in Q1 2024 [29] Business Line Data and Key Metrics Changes - The company experienced broad-based demand for existing technologies and rapid adoption of new solutions launched in 2024 [7][39] - The number of physicians performing procedures using the company's products grew by 27%, with over 1,400 U.S. physicians engaged [19] - The number of four implant Granite cases grew approximately 69% compared to the prior year period [13] Market Data and Key Metrics Changes - The total addressable market has increased to over $3.5 billion, with a cumulative procedure volume growth of 25% over the last three years [9][10] - The company is targeting nearly 100,000 degenerative procedures annually with its Granite product, which became eligible for transitional pass-through payment starting January 1, 2025 [13][14] Company Strategy and Development Direction - The company focuses on innovation, engagement, commercial execution, and operational excellence as key priorities [9] - The strategy includes diversifying the product platform with unique yet complementary technologies to expand the target modalities and physician footprint [9][10] - The company aims to reach 100 territories over the next 12 to 15 months, leveraging a hybrid commercial model combining territory managers and third-party agents [24][58] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver strong results over the long term, supported by resilient business trends and favorable reimbursement conditions [8][9] - The updated full-year revenue guidance is between $193.5 million to $197.5 million, implying year-over-year growth of approximately 16% to 18% [32] - Management noted that the company is well-positioned to achieve free cash flow in 2026, with a focus on maintaining operational discipline [30][32] Other Important Information - The company has a strong pipeline of novel technologies under development, with plans to launch new products over the next 12 to 18 months [16][18] - The company does not anticipate any material impact on gross margins or supply chain from proposed tariffs, as most manufacturing is domestic [30][31] Q&A Session Summary Question: Contribution from new products and channels to growth - Management noted broad-based growth and strong demand for current solutions, with impressive adoption of new products launched in 2024 [39] Question: Drivers of gross margin and future expectations - Management highlighted better-than-expected average selling price (ASP) and efficiency initiatives as key drivers of gross margin improvement [42][44] Question: Long-term growth expectations - Management expressed confidence in sustained growth potential, driven by technology leadership and expanding physician engagement [53][56] Question: Expected cadence of new guidance and sequential growth - Management indicated that while they do not think about the business in quarters, they expect to manage seasonality effectively with new product rollouts [66] Question: Operating expenses guidance - Management explained that elevated R&D investments and higher commissions linked to revenue growth are driving the expected increase in operating expenses [70][72] Question: Update on surgeon base and engagement - Management reported a record increase in the physician base, with broad engagement across various specialties [76][78] Question: Updates on reimbursement proposals - Management provided insights on CMS proposals and the potential for increased reimbursement rates, which could accelerate adoption of products [80][81] Question: Traction and adoption of TNT product - Management noted that TNT is seeing rapid adoption and is expected to benefit from upcoming reimbursement changes [97]

Core Viewpoint - The company reported a slight decline in revenue and profit for 2024 but showed signs of recovery in Q1 2025, indicating improved operational conditions. Financial Performance - In 2024, the company achieved an operating revenue of 377 million yuan and a net profit attributable to shareholders of 27.42 million yuan, reflecting a year-on-year decline [1] - In Q1 2025, the company’s operating revenue increased by 3.67% year-on-year to 94.80 million yuan, with a net profit growth of 3.30% to 14.87 million yuan, indicating a recovery [1] Business Segments - The company operates in three main business segments: biomaterials, pharmaceuticals, and cell therapy, with a focus on high-value consumables and innovative medical devices [1] - The medical device segment's revenue remained stable, with a notable 21.52% increase in revenue from B-type dura (spinal) patches, reaching 72.14 million yuan [2] Pharmaceutical Developments - The company’s 1.1 class new drug, Benvimod cream, is recognized as a potential blockbuster, effective for inflammatory and autoimmune diseases, and is included in multiple treatment guidelines [2] - Benvimod has broad application prospects beyond psoriasis, including atopic dermatitis and ulcerative colitis, with ongoing Phase III clinical trials for atopic dermatitis [2] Cell Therapy Initiatives - The company is enhancing its capabilities in immune and stem cell preparation technologies, clinical efficacy, and safety assessments, with a focus on regulatory compliance [3] - Revenue from cell technology services has exceeded 10%, with expectations for further growth as the regulatory environment improves [3] Research and Development - The company is advancing its bioartificial liver project, focusing on the pharmaceutical research of cell drugs and the performance study of related medical devices [4] - Collaborations with hospitals for preclinical research are underway, which could lead to significant growth opportunities if successful [4]

Core Viewpoint - The company experienced a significant decline in revenue and net profit in 2024 due to macroeconomic conditions and industry policy impacts, but there are signs of recovery in 2025 with new product approvals and improved sales in various segments [1][2]. Group 1: Financial Performance - In 2024, the company reported revenue of 6.103 billion yuan, net profit attributable to shareholders of 247 million yuan, and net profit excluding non-recurring items of 221 million yuan, reflecting year-over-year declines of 23.5%, 80.4%, and 80.3% respectively [1]. - For Q1 2025, the company achieved revenue of 1.736 billion yuan, net profit attributable to shareholders of 379 million yuan, and net profit excluding non-recurring items of 337 million yuan, showing year-over-year declines of 9.7%, 21.4%, and 26.1% respectively, but with quarter-over-quarter improvements [1]. - The company expects a recovery in 2025 driven by new product approvals and a gradual restoration of its generic drug business [1]. Group 2: Business Segments - The structural heart disease segment showed strong performance with revenues of 3.326 billion yuan in 2024 and 904 million yuan in Q1 2025, marking year-over-year growth of 44.0% and 37.4% respectively [2]. - The pharmaceutical segment reported revenues of 1.758 billion yuan in 2024 and 595 million yuan in Q1 2025, with a year-over-year decline of 42.3% in 2024 but a significant quarter-over-quarter improvement of 111.4% in Q1 2025 [2]. - The medical services and health management segment generated revenues of 1.019 billion yuan in 2024 and 238 million yuan in Q1 2025, with year-over-year declines of 19.2% and 2.4% respectively, but is expected to improve with new product launches [2]. Group 3: Product Development - The company has expanded its product matrix, with several cardiovascular devices approved for market, including various catheter types and a biodegradable left atrial appendage occluder [3]. - In pharmaceuticals, the company is advancing its GLP-1 class products and has completed clinical trials for several key drugs, including a biosimilar for dulaglutide [3]. - Other product developments include continuous glucose monitoring systems and ongoing research in ophthalmology and dermatology [3]. Group 4: Profit Forecast and Valuation - The company anticipates net profits of 1.003 billion yuan, 1.156 billion yuan, and 1.331 billion yuan for 2025-2027, reflecting downward adjustments of 34% and 36% for 2025 and 2026 respectively [4]. - Given the diverse business layout and comprehensive sales channels, the company is assigned a 24x PE valuation for 2025, leading to a target price of 12.81 yuan [4].

一次创新思维的碰撞，一场探索医疗科技创新的合作之旅！ 医生 ×CEO ×工程师 ×投资人 强强联合，破解医疗器械创新难题！ 如果你对 医疗器械创新、医工结合、技术转化 充满兴趣，那么这次 上海交通大学医学院 × 附属医院 × 生物医学工程学院 联合打造的 「医疗器械医工创新转化工作 坊」 ，就是你的绝佳机会！ 课程亮点 你将获得 培训信息 时间： 2025年6月（周末2天，具体时间提前一个月通知） 地点： 上海交通大学医学院 费用： 8999元/人（含课程、教材、茶点等，食宿自理） 主办单位： 上海交通大学医学院继续教育学院 支持 单位： 中关村联新生物医药产业联盟 第一天：医疗创新与技术布局 晚上：技术解决方案对接会 第二天：创新产业化与资金路径 医工创新产业的关键点及资金来源 课程安排 课程安排 | 2天高强度实战训练，全面掌握医工创新转化 让医学痛点与工程技术深度融合，打造医疗创新产品，助力成果转化！ 是否曾有一个医疗创新的想法，却不知如何落地？ 是否苦于医生与工程技术团队难以有效协作？ 是否希望掌握医疗器械从概念到市场的完整路径？ Biodesign 医工创新方法论： 全球前沿医工创新模式，助力高效转 ...

报名：首届全球眼科大会 | 议程更新 报名：首届全球骨科大会 | 议程更新 报名：首届全球心血管大会 | 奖项申报 合作伙伴征集：2025全球手术机器人大会 近日，中国植入式给药装置领域的创新先锋—— 炜璨医疗 宣布 完成数千万元天使轮融资 。本轮融资由元禾 原点和诺庾资本联合领投，南京江北科投跟投。 此前，公司还获得了华创资本 数千万元种子轮 融资。 本轮 资金将主要用于加快第一代产品上市步伐、加速新一代产品研发以及推动颠覆性创新产品的项目落地。 # 关于炜璨医疗 炜璨医疗成立于2023年4月11日，总部位于江苏省南京市。公司是一家 专注于传统肿瘤介入通路与植入式智 能化介入产品 的创新型医疗器械公司， 聚焦介入式医疗器械与智能化技术赛道 。公司早期采用国际国内成熟 技术储备，依靠企业自研团队开发静脉、动脉、镇痛、腹腔、透析通路等各种应用场景下的植入式给药装置系 列产品，其中大量产品为国内外首创。 产品与技术 炜璨医疗的产品线主要围绕植入式给药装置展开，其核心产品包括 静脉、动脉、镇痛、腹腔、透析通路等各 种应用场景下的植入式给药装置 。公司采用校企联合研发模式，与创新型新材料团队合作，打磨了可以国产 替代 ...

Financial Data and Key Metrics Changes - Total worldwide revenue for Q3 2025 was $72 million, representing a year-over-year growth of over 9% [9][28] - Adjusted EBITDA was $1.3 million, compared to a loss of $3.6 million in the prior year [38] - Gross margin increased to 54%, up 290 basis points from the previous year [33] Business Line Data and Key Metrics Changes - MedTech segment revenue was $31.3 million, a 22.2% increase year-over-year [28] - Mechanical Thrombectomy revenue, including AlphaVac and AngioVac, grew 46.7% year-over-year [30] - AlphaVac revenue increased by 161.4% year-over-year, reaching $3 million [30] - AngioVac generated $6.8 million in revenue, representing a 23.1% growth [30] Market Data and Key Metrics Changes - MedTech platforms comprised 44% of total revenue, up from 39% a year ago [28] - Auryon platform contributed $13.9 million in revenue, growing 17.3% compared to last year [29] - NanoKnife revenue was $6.3 million, an increase of 5.3% [31] Company Strategy and Development Direction - The company is focused on driving profitable growth in high-margin MedTech markets [10] - Plans to leverage the momentum built in the U.S. market for Auryon and expand internationally following CE marking [48] - Continued investment in clinical data and product enhancements to support long-term adoption of technologies [49] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving cash flow positivity for the full fiscal year 2026 [44] - The company is monitoring the macro environment and potential tariffs but does not expect a material impact on business [34] - Increased guidance for fiscal 2025 includes revenue expectations of $285 million to $288 million, reflecting growth of 5.3% to 6.4% [45] Other Important Information - The company has secured a revolving line of credit agreement with J.P. Morgan for $25 million [41] - R&D expenses were $6.9 million, or 9.6% of sales, down from $8.1 million, or 12.2% of sales, a year ago [36] Q&A Session Summary Question: Is the $6.8 million revenue for AngioVac a good new base for the business going forward? - Management believes that $6.8 million is a solid base for AngioVac, expecting it to continue as a growth platform [54][56] Question: Can you provide details on NanoKnife's revenue and marketing efforts? - Management noted that prostate treatments have become the leading application for NanoKnife, with increasing monthly treatment rates [62] Question: What is the update on the AMBITION study and its significance? - The AMBITION study is expected to begin enrollment soon, aiming to demonstrate Auryon's effectiveness below the knee [85][88]

预计2024年净亏损不超过2.75亿美元（约合19.9亿元人民币）， 较上年同期亏损收窄超过 58% 。亏损的显 著收窄主要归因于资源聚焦和成本优化措施，使得经营费用占收入比率同比下降约28个百分点。 报名：首届全球眼科大会 | 暂定议程 报名：首届全球心血管大会 | 奖项报名倒计时 报名：首届全球骨科大会 | 奖项报名倒计时 2025年3月9日，微创医疗（00853.HK）发布了2024年度业绩预告。 # 财务数据 收入增长 尽管面临快速变化的外部环境和行业政策影响，微创医疗预计2024年收入同比增长近10%，剔除汇率影响 后， 收入预计达到 74.07亿 元人民币 。 净亏损收窄 合作伙伴征集：2025全球手术机器人大会 海外业务增长 通过全球化平台的协同效应， 微创医疗出海业务收入同比增长约 80% ，进一步推动了整体收入增长。 产品注册与创新 报告期内，集团及联营公司共有6款产品进入国家创新医疗器械审批程序（绿色通道）， 累计达到36款，连 续十年在同行业中排名第一 。此外，集团及联营公司共获得46项国家药品监督管理局颁发的三类医疗器械首 次注册证，并在43个海外市场获得184项首次注册证，其中包括1 ...